Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
w0Wq698MUKTP1mJE
